SION trades 20.2% below Wall Street's consensus target of $54.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SION achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Sionna Therapeutics, Inc. (SION) has a Wall Street consensus price target of $54.00, based on estimates from 7 covering analysts. With the stock currently trading at $44.93, this represents a potential upside of +20.2%. The company has a market capitalization of $2.03B.
Analyst price targets range from a low of $50.00 to a high of $58.00, representing a 15% spread in expectations. The median target of $54.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SION trades at a trailing P/E of -23.9x. Analysts expect EPS to grow -35.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $132.8B | $522.25 | $556.00 | +6.5% | Buy | 27.1x | 56 |
ABBVAbbVie Inc. | $449.9B | $254.65 | $258.00 | +1.3% | Buy | 17.9x | 41 |
PTCTPTC Therapeutics, Inc. | $7.4B | $89.20 | $95.83 | +7.4% | Buy | 100.7x | 26 |
RAREUltragenyx Pharmaceutical Inc. | $3.5B | $35.87 | $47.11 | +31.3% | Buy | — | 33 |
KRYSKrystal Biotech, Inc. | $10.9B | $368.60 | $336.40 | -8.7% | Buy | 48.0x | 17 |
GILDGilead Sciences, Inc. | $169.3B | $136.36 | $161.81 | +18.7% | Buy | — | 58 |
ALNYAlnylam Pharmaceuticals, Inc. | $42.9B | $321.59 | $450.64 | +40.1% | Buy | 43.2x | 52 |
IONSIonis Pharmaceuticals, Inc. | $14.3B | $86.33 | $106.50 | +23.4% | Buy | — | 32 |
EDITEditas Medicine, Inc. | $367M | $3.75 | $5.00 | +33.3% | Buy | — | 25 |
BEAMBeam Therapeutics Inc. | $3.9B | $37.92 | $48.00 | +26.6% | Buy | — | 27 |
Quick answers to the most common questions about buying SION stock.
The consensus Wall Street price target for SION is $54, representing 20.2% upside from the current price of $44.93. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SION has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $54 implies 20.2% upside from current levels.
SION's current price is $44.93 with a consensus target of $54 (20.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $58 for SION, while the most conservative target is $50. The consensus of $54 represents the median expectation. These targets typically reflect 12-month expectations.
SION is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SION stock forecast based on 7 Wall Street analysts shows a consensus price target of $54, with estimates ranging from $50 (bear case) to $58 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SION, with a "Buy" consensus rating and $54 price target (20.2% upside). 5 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SION analyst price targets range from $50 to $58, a 15% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $54 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.